Titled "Unite and Upgrade for a Better Future", the 2nd International Biopharma Industry Week Shanghai was officially inaugurated. On November 17, Dr. Liu Datao, co-founder and CEO of Mabwell, and He Jing, Vice Chairman of DIA China Regional Advisory Council and R & D Senior Vice-President of AstraZeneca, were invited to participate in the "International Biopharma Industry Week Shanghai 2022" media live broadcast hosted by Yicai.

During the interview on the topic "Focusing on translational medicine and multi-center clinical studies, and taking new steps in the global layout", Dr. Liu Datao pointed out that translational medicine is an effective tool for accelerating biopharmaceutical research and development by focusing on solving clinical problems, conducting targeted research, greatly accelerating the process of drug development and improving the success rate of research and development. China's multi-center clinical studies have been in line with international standards, and the data generated have been recognized internationally, which can help bring Chinese drugs to international markets rapidly.

In recent years, the emergence of new targets and drugs has brought about subversive changes in the treatment of many tumors. These are the achievements of translational medicine, including the first-in-China and second-in-the-world ADC drug targeting Nectin-4 independently developed by Mabwell Bioscience, which is currently undergoing multiple clinical trials in China and the United States.